# Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

> **NCT04028063** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 65 (estimated)

## Conditions studied

- Metastatic Soft Tissue Sarcoma
- Advanced Soft Tissue Sarcoma

## Interventions

- **DRUG:** Balstilimab
- **DRUG:** Zalifrelimab
- **DRUG:** Doxorubicin
- **DRUG:** Botensilimab

## Key facts

- **NCT ID:** NCT04028063
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-28
- **Primary completion:** 2027-04-07
- **Final completion:** 2027-12-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04028063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04028063, "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04028063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*